Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Equine Vet J ; 45(2): 235-9, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22943193

ABSTRACT

REASONS FOR PERFORMING STUDY: During the 2007 Australian equine influenza (EI) outbreak, an accelerated primary course 14 day intervaccination schedule was proposed, but not widely implemented. Expert opinion was divided as to the efficacy of such a schedule given the lack of published data. This study determined the level and duration of humoral immunity following administration of a recombinant canarypox-vectored vaccine (ALVAC-EIV) with a primary intervaccination interval of 14 days and booster at 105 days. OBJECTIVES: To examine whether protective levels of immunity of adequate duration were achieved following a primary course reduced from a minimum interval of 28 to 14 days. Antibody responses to 2 H3N8 American lineage virus strains (including A/equine/Sydney/6085/2007) were assessed and compared to previous challenge studies using ALVAC-EIV at conventional intervaccination intervals. METHODS: Fourteen Thoroughbred horses and 2 ponies from a rural racehorse training property in Victoria, Australia, were vaccinated with ALVAC-EIV on Days 0, 14 and 105. Serial blood samples were collected over the next 32 weeks and tested with haemagglutination inhibition and single radial haemolysis (SRH) in full assays to evaluate the serological response. RESULTS: All horses and ponies responded to the accelerated ALVAC-EIV vaccination schedule. Mean SRH antibodies remained above those consistent with clinical protection for the duration of the study period. All vaccinates demonstrated high SRH antibodies 14 days following V2, thereby achieving 100% herd immunity to homologous viral challenge. CONCLUSIONS: An accelerated vaccination schedule conferred long-lasting protective antibody levels despite a >50% reduction in the recommended V1-V2 interval. POTENTIAL RELEVANCE: High levels of rapidly acquired herd immunity are critical in containing an outbreak of such a highly contagious pathogen as EIV. In a strategic vaccination programme, it is important that horses remain protected for sufficient time to allow control programmes to succeed. An accelerated 14 day primary course intervaccination interval and booster at 105 days achieves both of these objectives.


Subject(s)
Antibodies, Viral/blood , Horse Diseases/prevention & control , Influenza Vaccines/immunology , Orthomyxoviridae Infections/veterinary , Animals , Horses , Immunization Schedule , Influenza Vaccines/administration & dosage , Orthomyxoviridae Infections/prevention & control , Vaccination
2.
Vet Immunol Immunopathol ; 149(1-2): 76-85, 2012 Sep 15.
Article in English | MEDLINE | ID: mdl-22763149

ABSTRACT

A recombinant canarypox virus vectored vaccine co-expressing synthetic genes encoding outer capsid proteins, VP2 and VP5, of African horse sickness virus (AHSV) serotype 4 (ALVAC(®)-AHSV4) has been demonstrated to fully protect horses against homologous challenge with virulent field virus. Guthrie et al. (2009) detected weak and variable titres of neutralizing antibody (ranging from <10 to 40) 8 weeks after vaccination leading us to hypothesize that there could be a participation of cell mediated immunity (CMI) in protection against AHSV4. The present study aimed at characterizing the CMI induced by the experimental ALVAC(®)-AHSV4 vaccine. Six horses received two vaccinations twenty-eight days apart and three horses remained unvaccinated. The detection of VP2/VP5 specific IFN-γ responses was assessed by enzyme linked immune spot (ELISpot) assay and clearly demonstrated that all ALVAC(®)-AHSV4 vaccinated horses developed significant IFN-γ production compared to unvaccinated horses. More detailed immune responses obtained by flow cytometry demonstrated that ALVAC(®)-AHSV4 vaccinations induced immune cells, mainly CD8(+) T cells, able to recognize multiple T-epitopes through all VP2 and only the N-terminus sequence of VP5. Neither VP2 nor VP5 specific IFN-γ responses were detected in unvaccinated horses. Overall, our data demonstrated that an experimental recombinant canarypox based vaccine induced significant CMI specific for both VP2 and VP5 proteins of AHSV4.


Subject(s)
African Horse Sickness Virus/immunology , African Horse Sickness/immunology , African Horse Sickness/prevention & control , Canarypox virus/genetics , Capsid Proteins/immunology , Viral Vaccines/administration & dosage , African Horse Sickness Virus/genetics , Animals , Capsid Proteins/genetics , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry/veterinary , Horses , Immunity, Cellular/immunology , Immunization/veterinary , Interferon-gamma/blood , Male , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Viral Vaccines/genetics , Viral Vaccines/immunology
3.
Aust Vet J ; 89 Suppl 1: 137-9, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21711312
4.
Vaccine ; 29(28): 4608-12, 2011 Jun 20.
Article in English | MEDLINE | ID: mdl-21549780

ABSTRACT

The emergence of lineage 2 strains of WNV in Europe as a cause of clinical disease and mortality in horses raised the question whether the existing WNV vaccines, all based on lineage 1 strains, protect against circulating lineage 2 strains of WNV. In the present paper we have determined the level of cross protection provided by the recombinant ALVAC(®)-WNV vaccine in a severe challenge model that produces clinical signs of WNV type 2 disease. Ten horses were vaccinated twice at 4 weeks interval with one dose of the ALVAC-WNV vaccine formulated at the minimum protective dose. A further 10 horses served as controls. Two weeks after the second vaccination, all horses were challenged intrathecally with a recent neurovirulent lineage 2 strain of WNV. The challenge produced viraemia in 10 out of 10 and encephalitis in 9 out of 10 control horses. Three horses had to be euthanized for humane reasons. In contrast, none of the vaccinated horses developed WNV disease and only 1 vaccinated horse became viraemic at a single time point at low titre. The prevalence of WNV disease and viraemia were significantly lower in the vaccinated horses than in the control horses (P<0.0001 for both). Based on these results, the ALVAC-WNV vaccine will provide veterinarians with an effective tool to control infections caused by lineage 1 and 2 strains of WNV.


Subject(s)
Horse Diseases/prevention & control , Vaccines, Synthetic/administration & dosage , Viral Vaccines/administration & dosage , West Nile Fever/prevention & control , West Nile Virus Vaccines/administration & dosage , West Nile virus/pathogenicity , Animals , Antibodies, Viral/immunology , Cross Protection , Female , Horse Diseases/immunology , Horse Diseases/virology , Horses , Male , Treatment Outcome , Vaccination/veterinary , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Viral Envelope Proteins/metabolism , Viral Vaccines/genetics , Viral Vaccines/immunology , West Nile Fever/immunology , West Nile Fever/veterinary , West Nile Fever/virology , West Nile Virus Vaccines/genetics , West Nile Virus Vaccines/immunology , West Nile virus/classification , West Nile virus/genetics , West Nile virus/immunology
5.
Vet Microbiol ; 137(1-2): 137-45, 2009 May 28.
Article in English | MEDLINE | ID: mdl-19179023

ABSTRACT

Protection against clinical disease and prevention of the renal carrier state remain the key objectives of vaccination against leptospirosis in the dog. In the present paper, groups of dogs were vaccinated twice with a commercial bacterin (EURICAN L) containing Leptospira interrogans serovars icterohaemorrhagiae and canicola and challenged with heterologous representatives of both serovars at 2 weeks (onset of immunity) or 14 months (duration of immunity) after the second vaccination. Control dogs were not vaccinated against leptospirosis and kept with the vaccinated dogs. The challenges, irrespective of the serovar, reliably produced clinical signs consistent with Leptospira infection in the control pups with up to 60% mortality. As expected clinical disease in the adult controls was less severe, but we were able to induce morbidity and mortality as well. Under these extreme challenge conditions, clinical signs in the vaccinated dogs were rare, and when observed, mild and transient in nature. Following experimental infection, 100% of the control pups and 83% of the adult controls became renal carriers. Despite the heavy challenges, none of the 18 vaccinated puppies (onset of immunity studies) and only 2 out of the 16 vaccinated adult dogs (duration of immunity studies) developed a renal carrier state. These results show that a primary course of two doses of EURICAN L provided quick onset and long-term protection against both clinical leptospirosis and the renal carrier stage. This vaccine should provide veterinarians with a powerful tool to prevent clinical disease in dogs and zoonotic transmission of leptospirosis to humans.


Subject(s)
Bacterial Vaccines/immunology , Carrier State/veterinary , Dog Diseases/prevention & control , Kidney/microbiology , Leptospirosis/veterinary , Animals , Antibodies, Bacterial/blood , Bacteremia , Carrier State/immunology , Carrier State/prevention & control , Dog Diseases/blood , Dog Diseases/microbiology , Dog Diseases/urine , Dogs , Female , Leptospira interrogans serovar canicola/immunology , Leptospira interrogans serovar icterohaemorrhagiae/immunology , Leptospirosis/epidemiology , Leptospirosis/prevention & control , Leptospirosis/urine , Liver/microbiology , Male
6.
Vet Microbiol ; 133(3): 283-6, 2009 Jan 13.
Article in English | MEDLINE | ID: mdl-18757142

ABSTRACT

Thirty laboratory dogs were randomly assigned to two groups (A and B) of 15 dogs and subcutaneously vaccinated with a single dose of one of two commercially available monovalent inactivated rabies vaccines: RABISIN (Merial, France) (group A) and NOBIVAC Rabies (Intervet International) (group B). Rabies antibodies were measured over a period of 4 months using the fluorescent antibody virus neutralization (FAVN) test. The two vaccines performed differently in terms of magnitude and persistence of rabies antibodies titers in dogs. Two weeks after vaccination, average rabies antibody titers peaked at 2.53 IU/mL (range, 0.17-13.77 IU/mL) and 1.26 IU/mL (range, 0.50-4.56 IU/mL) in groups A and B dogs, respectively. The average FAVN antibody titres against rabies on D28, D56, D84, D112 and D120 were significantly higher in group A than in group B. Although all dogs from group B serologically responded to vaccination, the proportion of dogs with antibody titres >or=0.5 IU/mL dropped significantly after D28 and was statistically significantly lower on D56, D84 and D112 compared to group A dogs. In conclusion, in the context of international trade, the choice of the vaccine and the timing of blood tests are critical factors in achieving successful serological test results after rabies vaccination. RABISIN induces high and sustained antibody titres against rabies, increasing the flexibility for the time of blood sampling after primo-vaccination.


Subject(s)
Antibodies, Viral/blood , Dog Diseases/immunology , Rabies Vaccines/immunology , Rabies/immunology , Animals , Dog Diseases/blood , Dogs , Female , Male
7.
Vet Immunol Immunopathol ; 123(3-4): 230-9, 2008 Jun 15.
Article in English | MEDLINE | ID: mdl-18372050

ABSTRACT

Successful vaccination against West Nile virus (WNV) requires induction of both neutralizing antibodies and cell-mediated immune responses. In this study, we have assessed the ability of a recombinant ALVAC-WNV vaccine (RECOMBITEK WNV) to elicit neutralizing antibodies and virus-specific cell-mediated immune responses in horses. In addition, we examined whether prior exposure to ALVAC-WNV vaccine would inhibit B and cell-mediated immune responses against the transgene product upon subsequent booster immunizations with the same vaccine. The results demonstrated that the recombinant ALVAC-WNV vaccine induced neutralizing antibodies and prM/E insert-specific IFN-gamma(+) producing cells against WNV in vaccinated horses. Prior exposure to ALVAC-WNV vaccine did not impair the ability of horses to respond to two subsequent booster injections with the same vaccine, although anti-vector-specific antibody and cell-mediated immune responses were induced in vaccinated horses. This report describes, for the first time, the induction of antigen-specific cell-mediated responses following vaccination with an ALVAC virus recombinant vaccine encoding WNV antigens. Moreover, we showed that both WNV-specific IFN-gamma producing cells and anti-WNV neutralizing antibody responses, are not inhibited by subsequent vaccinations with the same vector vaccine.


Subject(s)
Antibodies, Viral/biosynthesis , Horse Diseases/prevention & control , Horses/immunology , Viral Vaccines/immunology , West Nile Fever/veterinary , West Nile Virus Vaccines/immunology , West Nile virus/immunology , Animals , Antibodies, Viral/blood , Antibodies, Viral/immunology , Enzyme-Linked Immunosorbent Assay/veterinary , Female , Horse Diseases/immunology , Horse Diseases/virology , Immunization, Secondary/veterinary , Interferon-gamma/blood , Male , Neutralization Tests/veterinary , Statistics, Nonparametric , Vaccination/methods , Vaccination/veterinary , Viral Vaccines/administration & dosage , West Nile Fever/immunology , West Nile Fever/prevention & control , West Nile Fever/virology , West Nile Virus Vaccines/administration & dosage
8.
Vaccine ; 25(42): 7385-98, 2007 Oct 16.
Article in English | MEDLINE | ID: mdl-17881098

ABSTRACT

Equine influenza virus (EIV) is a leading cause of respiratory disease in horses. Equine influenza infection induces a long-term immunity to re-infection. Recent strategies of vaccination aim to mimic this immunity by stimulating both antibody and cellular immune responses. Cell-mediated immunity (CMI) to influenza is well defined in man, but little has been done to characterise the responses in the horse. Additionally, the development of reliable assays for the measurement of equine CMI has lagged behind serological methods and vaccine development. In this study, two methods of measuring EIV-specific T lymphocyte responses have been developed. An EIV 'bulk' cytotoxic T lymphocytes (CTL) assay using equine dermal fibroblasts as target cells has been adapted from a method used in the 1980s. This method was also complemented with a new EIV-specific IFNgamma synthesis assay. When compared with the measurement of EIV-specific IFNgamma synthesis previously described, this method required the amplification of EIV-specific lymphocytes by culture and was sensitive enough to detect stimulation of EIV-specific T lymphocytes induced by experimental infection with EIV or vaccination with recombinant canarypox viruses coding for EIV-HA molecules. This study provides the tools to characterise the stimulation of CMI by the new generation of vaccines against equine influenza.


Subject(s)
Horses/immunology , Horses/virology , Influenza A Virus, H3N8 Subtype/immunology , Animals , Cells, Cultured , Horse Diseases/immunology , Horse Diseases/prevention & control , Horse Diseases/virology , Immunity, Cellular , Influenza A Virus, H3N8 Subtype/pathogenicity , Influenza Vaccines/immunology , Interferon-gamma/biosynthesis , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/prevention & control , Orthomyxoviridae Infections/veterinary , Orthomyxoviridae Infections/virology , Receptors, Virus/metabolism , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/virology
9.
J Comp Pathol ; 137 Suppl 1: S76-80, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17559865

ABSTRACT

A classical limitation of early life immunization is the interference by maternally derived antibodies, which are known to inhibit the immune response to modified-live and killed vaccines. Several studies have convincingly shown that even minute amounts of maternally derived antibodies against equine influenza can strongly interfere with successful vaccination of foals born to immune mares. In this study we evaluated the response of foals born to vaccinated mares to immunization with a canarypox-vectored recombinant vaccine against equine influenza virus H3N8. The recombinant vaccine was able to efficiently prime foals in the presence of maternally derived immunity against influenza as was evidenced by a clear anamnestic antibody response when a secondary vaccination with the same vaccine was performed. The canarypox-vectored recombinant influenza vaccine therefore offers a unique opportunity to overcome the limitations of early life vaccination in the face of maternally derived immunity in foals.


Subject(s)
Horse Diseases/prevention & control , Immunity, Maternally-Acquired/immunology , Influenza A Virus, H3N8 Subtype/immunology , Influenza Vaccines/therapeutic use , Orthomyxoviridae Infections/veterinary , Vaccines, Synthetic/therapeutic use , Animals , Antibodies, Viral/immunology , Antibodies, Viral/metabolism , Canarypox virus/genetics , Canarypox virus/immunology , Cross-Priming/immunology , Female , Horse Diseases/immunology , Horse Diseases/virology , Horses , Influenza Vaccines/immunology , Male , Orthomyxoviridae/genetics , Orthomyxoviridae/immunology , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/prevention & control , Vaccination/methods , Vaccination/veterinary , Vaccines, Synthetic/immunology
10.
Vet Immunol Immunopathol ; 112(3-4): 225-33, 2006 Aug 15.
Article in English | MEDLINE | ID: mdl-16621023

ABSTRACT

In horses, equine influenza virus (EIV) is a leading cause of respiratory disease. Conventional inactivated vaccines induce a short-lived immune response. By comparison, natural infection confers a long-term immunity to re-infection. An aim of new equine influenza vaccines is to more closely mimic natural infection in order to achieve a better quality of immunity. A new live recombinant vaccine derived from the canarypox virus vector and expressing haemagglutinin genes of EIV (subtype H3N8) has been developed. Stimulation of the immune system was studied after immunisation with this canarypox-based vaccine and challenge infection by exposure to a nebulised aerosol of EIV. The humoral immune response was evaluated by measuring serum antibody levels using the single radial haemolysis (SRH) assay. The cellular immune response was assessed by the measurement of interferon gamma (IFN-gamma) synthesis in peripheral blood mononuclear cells (PBMC). Clinical signs of the disease (temperature, coughing, nasal discharge, dyspnoea, depression and anorexia) and virus excretion were monitored after challenge infection. Clinical signs and virus shedding were significantly reduced in vaccinates compared with unvaccinated controls. EIV-specific immunity was stimulated by vaccination with a recombinant vaccine as serological responses were detected after immunisation. This study also provided the first evidence for increased IFN-gamma protein synthesis in vaccinated ponies following challenge infection with EIV compared with control ponies.


Subject(s)
Canarypox virus/immunology , Horse Diseases/immunology , Horse Diseases/virology , Influenza A Virus, H3N8 Subtype/immunology , Orthomyxoviridae Infections/veterinary , Vaccination/veterinary , Viral Vaccines/immunology , Animals , Antibodies, Viral/biosynthesis , Antibodies, Viral/blood , Body Temperature/immunology , Canarypox virus/genetics , Horses , Interferon-gamma/biosynthesis , Interferon-gamma/blood , Interferon-gamma/immunology , Leukocytes, Mononuclear/immunology , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/prevention & control , Orthomyxoviridae Infections/virology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/therapeutic use , Viral Vaccines/genetics , Viral Vaccines/therapeutic use
11.
Vet Immunol Immunopathol ; 111(1-2): 47-57, 2006 May 15.
Article in English | MEDLINE | ID: mdl-16580075

ABSTRACT

In this study, experimental canarypox virus (ALVAC) and plasmid DNA recombinant vaccines expressing the gB, gC and gD glycoproteins of EHV-1 were assessed for their ability to protect conventional ponies against a respiratory challenge with EHV-1. In addition, potential means of enhancing serological responses in horses to ALVAC and DNA vaccination were explored. These included co-administration of the antigen with conventional adjuvants, complexation with DMRIE-DOPE and co-expression of the antigen along with equine GM-CSF. Groups of EHV primed ponies were vaccinated twice intra-muscularly with one dose of the appropriate test vaccine at an interval of 5 weeks. Two to 3 weeks after the second vaccination, ponies were infected intra-nasally with the virulent Ab4 strain of EHV-1 after which they were observed clinically and sampled for virological investigations. The results demonstrated that DNA and ALVAC vaccination markedly reduced virus excretion after challenge in terms of duration and magnitude, but failed to protect against cell-associated viremia. Noteworthy was the almost complete absence of virus excretion in the group of ponies vaccinated with ALVAC-EHV in the presence of Carbopol adjuvant or DNA plasmid formulated with aluminium phosphate. The administration of the DNA vaccine in the presence of GM-CSF and formulated in DMRIE-DOPE and of the ALVAC vaccine in the presence of Carbopol adjuvant significantly improved virus neutralising antibody responses to EHV-1. These findings indicate that DNA and ALVAC vaccination is a promising approach for the immunological control of EHV-1 infection, but that more research is needed to identify the immunodominant protective antigens of EHV-1 and their interaction with the equine immune system.


Subject(s)
Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/immunology , Herpesvirus Vaccines/therapeutic use , Horse Diseases/prevention & control , Horse Diseases/virology , Vaccination/veterinary , Vaccines, DNA/therapeutic use , Viral Vaccines/therapeutic use , Adjuvants, Immunologic/pharmacology , Animals , Antibodies, Viral/blood , Female , Herpesviridae Infections/immunology , Herpesviridae Infections/prevention & control , Herpesviridae Infections/virology , Herpesvirus 1, Equid/genetics , Herpesvirus Vaccines/genetics , Herpesvirus Vaccines/immunology , Horse Diseases/immunology , Horses , Male , Neutralization Tests/veterinary , Polymerase Chain Reaction/veterinary , Statistics, Nonparametric , Vaccination/methods , Vaccines, DNA/immunology , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Viral Vaccines/genetics , Viral Vaccines/immunology
12.
Vaccine ; 24(10): 1490-500, 2006 Mar 06.
Article in English | MEDLINE | ID: mdl-16269205

ABSTRACT

Equine herpesvirus-1 (EHV-1) is a ubiquitous pathogen of horses, which continues to cause respiratory and neurological disease and abortion, despite the widespread use of vaccines. Cell mediated immunity (CMI) is thought to play a major role in protection against infection with EHV-1. The aim of this study was to characterise the virus-specific CMI response in ponies vaccinated with vP1014, a vaccinia-based construct (NYVAC) coding for the immediate early gene (gene 64) of EHV-1. This gene product is a CTL target protein for an equine MHC class I allele expressed on the A3 haplotype. EHV-primed yearling ponies expressing this haplotype were vaccinated once (n = 1), three (n = 1), or four times (n = 2), and one pony was kept as an unvaccinated control. Cytotoxic T lymphocyte (CTL) activity and interferon gamma (IFN-gamma) synthesis were measured before and after vaccination and challenge infection with EHV-1. Multiple immunisations with vP1014 resulted in increased CTL activity and IFN-gamma synthesis specific for EHV-1 compared with unvaccinated or singly vaccinated ponies. The phenotype of EHV-1 specific T-cells synthesising IFN-gamma was also modified by immunisation. In the unvaccinated pony, the predominant population synthesising IFN-gamma after EHV-1 stimulation was CD8alpha+. In contrast, multiply vaccinated ponies demonstrated an increased proportion of CD8alpha- T-cells synthesising IFN-gamma. The results demonstrated that vaccination with a NYVAC-based construct coding for gene 64 stimulated CMI. This immune response alone did not protect against challenge infection. However, the study does illustrate that vaccinia-based vaccines can stimulate CMI in the horse and may therefore contribute to protection against disease caused by EHV-1.


Subject(s)
Genes, Immediate-Early , Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/immunology , Herpesvirus Vaccines/immunology , Horse Diseases/prevention & control , Interferon-gamma/biosynthesis , T-Lymphocytes, Cytotoxic/immunology , Vaccines, DNA/immunology , Animals , Antibodies, Viral/biosynthesis , Female , Herpesviridae Infections/prevention & control , Horses , Immunophenotyping , Male , Vaccination
13.
Vaccine ; 23(29): 3808-13, 2005 May 31.
Article in English | MEDLINE | ID: mdl-15893618

ABSTRACT

The safety and efficacy of a canarypox vector expressing PrM and E genes of West Nile virus (WNV) (ALVAC-WNV) was evaluated in dogs and cats. One group of 17 dogs (vaccinated with 10(5.6) TCID(50)) and two groups of cats (groups 1 [n=14] vaccinated with 10(7.5) TCID(50) and 2 [n=8] 10(5.6) TCID(50)) were vaccinated twice at 28-day intervals. Fifteen dogs and eleven cats served as negative controls. The cats and dogs were challenged 120 and 135 days after the second immunization, respectively via the bites of Aedes albopictus mosquitoes infected with WNV. The first dose of vaccine induced a detectable antibody response in four dogs and five cats (one immunized with low and four with high doses). After the second dose, all the vaccinated dogs and all of the cats, immunized with high dose had detectable antibody titers, whereas only four of eight cats in the low dose group were seropositive. None of the vaccinated dogs and one vaccinated cat developed viremia following the WNV mosquito-challenge. In contrast, 14 of the 15 control dogs and 9 of the 11 control cats developed viremia. The experimental vaccine described in this study may be of value in the prevention of WNV infection in dogs and cats.


Subject(s)
Cat Diseases/prevention & control , Dog Diseases/prevention & control , Viral Vaccines/immunology , West Nile Fever/veterinary , West Nile virus/immunology , Animals , Antibodies, Viral/blood , Canarypox virus/genetics , Cats , Dogs , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/virology , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Viral Vaccines/adverse effects , Viral Vaccines/genetics , West Nile Fever/prevention & control , West Nile virus/genetics
14.
Vaccine ; 23(36): 4541-51, 2005 Aug 22.
Article in English | MEDLINE | ID: mdl-15913852

ABSTRACT

Equine cytotoxic T lymphocyte (CTL) responses to equine herpesvirus-1 (EHV-1) are well characterised but little is known about the cytokine response after infection or vaccination. EHV-1 is common in horses and infects lymphocytes in vivo. This virus was used as a model to measure the synthesis of interferon gamma (IFN-gamma) by equine peripheral blood mononuclear cells (PBMC) after in vivo infection and/or in vitro stimulation with EHV-1. Both flow cytometry and ELISPOT assays were used to quantify equine IFN-gamma using a mouse anti-bovine IFN-gamma monoclonal antibody (clone CC302; shown to cross-react with recombinant equine IFN-gamma) and a rabbit anti-canine IFN-gamma polyclonal antibody. The percentage of PBMC synthesising IFN-gamma after in vitro stimulation with EHV-1 increased with age. In yearlings infected experimentally with EHV-1, PBMC showed two peaks of IFN-gamma synthesis, 11 and 56 days after infection. The IFN-gamma synthesis was principally associated with CD8(+) cells. The patterns of IFN-gamma synthesis detected by intracellular IFN-gamma staining or ELISPOT were compared with CTL data and shown to be similar. These methods were also applied successfully to frozen samples of PBMC. Measurement of equine IFN-gamma using these simple techniques can now be applied to future studies on protective cellular immune responses following virus infection and/or vaccination of horses.


Subject(s)
Herpesviridae Infections/veterinary , Herpesvirus 1, Equid/immunology , Horse Diseases/prevention & control , Interferon-gamma/biosynthesis , Lymphocytes/immunology , Age Factors , Animals , Cryopreservation , Herpesviridae Infections/immunology , Herpesviridae Infections/prevention & control , Horse Diseases/immunology , Horses , Leukocytes, Mononuclear/immunology , Male , T-Lymphocytes, Cytotoxic/immunology
15.
Vet Rec ; 156(12): 367-71, 2005 Mar 19.
Article in English | MEDLINE | ID: mdl-15816180

ABSTRACT

Fifteen influenza-naive Welsh mountain ponies were randomly assigned to three groups of five. A single dose of a recombinant ALVAC vaccine was administered intramuscularly to five of the ponies, two doses, administered five weeks apart, were administered to five, and the other five served as unvaccinated, challenge controls. Two weeks after the completion of the vaccination programme, the ponies were all challenged by exposure to an aerosol of influenza virus A/eq/Newmarket/5/03. Their clinical signs were scored daily for 14 days according to a standardised scoring protocol, and nasal swabs were taken daily for 10 days to monitor the excretion of virus. The challenge produced severe clinical signs of influenza (fever, coughing, nasal discharge and dyspnoea) in all five control ponies, but the vaccinated ponies developed only mild disease, consisting of a serous nasal discharge lasting for only one day. The excretion of virus was almost completely suppressed in the vaccinated ponies, but the control ponies shed the virus for up to seven days after the challenge.


Subject(s)
Horse Diseases/prevention & control , Influenza A Virus, H3N8 Subtype , Influenza A virus/immunology , Influenza Vaccines , Orthomyxoviridae Infections/veterinary , Animals , Antibodies, Viral/blood , Body Temperature , Disease Outbreaks/veterinary , Horses , Immunization Schedule , Influenza Vaccines/administration & dosage , Male , Orthomyxoviridae Infections/prevention & control , United Kingdom , Vaccines, Synthetic/administration & dosage
16.
Arch Virol Suppl ; (18): 221-30, 2004.
Article in English | MEDLINE | ID: mdl-15119777

ABSTRACT

An ALVAC (canarypoxvirus)-based recombinant (vCP2017) expressing the prM and E genes derived from a 1999 New York isolate of West Nile virus (WNV) was constructed and assessed for its protective efficacy in horses in two different experiments. In the first trial, a dose titration study was conducted to evaluate both serum neutralising antibody responses to WNV and duration of immunity. In the second trial the onset of protection was determined. Twenty-eight adult horses received two doses of vCP2017 administered intramuscularly at 5-week intervals and sixteen horses comprised age-matched non-vaccinated controls. Individual sera were taken periodically and tested for neutralising antibodies against WNV. Horses were challenged by allowing WNV-infected Aedes albopictus mosquitoes to feed on them two weeks (second trial) or one year (first trial) after the second vaccination. After challenge, horses were monitored for clinical signs of disease, and blood samples were collected for detection of WNV viremia and antibody. In both trials, all vaccinated horses developed neutralising antibodies against WNV. None of the vaccinated or control horses developed clinical signs of WNV disease upon challenge. None of the nine horses challenged 2 weeks after primary vaccination and only one of the ten vaccinated horses challenged 1 year after vaccination developed detectable viremia after challenge, whereas more than 80% of the controls became infected. Results from these studies demonstrated that a primary course of two doses of vCP2017 provides both antibody response and an early immunity in horses against WNV viremia.


Subject(s)
Canarypox virus/immunology , Culicidae/virology , Horse Diseases/virology , Horses/immunology , Vaccines, Attenuated/therapeutic use , Vaccines, Synthetic/therapeutic use , Viral Vaccines/therapeutic use , West Nile Fever/immunology , West Nile Fever/veterinary , West Nile virus/immunology , Animals , Base Sequence , Cloning, Molecular , DNA Primers , Horse Diseases/immunology , Male , Plasmids/genetics , Polymerase Chain Reaction/methods , Viral Plaque Assay , West Nile virus/isolation & purification
17.
Vet Ther ; 5(4): 251-7, 2004.
Article in English | MEDLINE | ID: mdl-15719324

ABSTRACT

A new recombinant West Nile virus (WNV) vaccine has been licensed for use in horses. Prior to the availability of the recombinant vaccine in 2004, the only equine WNV vaccine available on the market had been an inactivated vaccine. Since the recombinant vaccine only expresses selected viral genes, the question could be posed as to whether a single dose of the recombinant vaccine would be effective in producing an anamnestic serologic response in horses previously vaccinated with an inactivated WNV vaccine. In this study we demonstrate that vaccination of horses with a canarypox-vectored recombinant vaccine, under field conditions, results in a marked anamnestic response in horses previously vaccinated with an inactivated WNV vaccine.


Subject(s)
Antibodies, Viral/blood , Horse Diseases/prevention & control , Viral Vaccines/immunology , West Nile Fever/veterinary , West Nile virus/immunology , Animals , Canarypox virus/genetics , Female , Horses , Male , Random Allocation , Vaccines, Inactivated/immunology , Vaccines, Synthetic/immunology , Viremia/veterinary , West Nile Fever/prevention & control
19.
Cancer Lett ; 73(2-3): 191-205, 1993 Sep 30.
Article in English | MEDLINE | ID: mdl-7693329

ABSTRACT

Immunohistochemical and biochemical procedures were used to study the influence of retinoic acid (RA) on cellular expression and distribution of cytokeratins (CKs) in feline mammary carcinoma cells. These cells were grown in vitro as established cell lines (K248C and K266) and in vivo as xenografts in athymic mice. The results were compared with the distribution of CKs in normal feline mammary gland and in a series of invasive mammary carcinomas previously probed with a panel of monoclonal antibodies specific for individual CKs. Coexpression of CKs of both major mammary gland cell types (myoepithelial cells, MECs, CKs 5/14 positive, and luminal epithelial cells, LECs CKs8/18 positive) by K248C and K266 cells, suggested a stem cell-like character of both cell lines. RA increased CK19 expression in both cell lines and CK19 was also present in tumors developed in nude mice from both RA untreated (CK19 negative) and RA-treated (CK19 positive) K248C and K266 cells. In addition, RA had cell line specific effects as well. RA treatment induced differentiation of K248C cells to more mature LEC-like cells and this change was accompanied by the loss of the MEC keratins CKs 5/14. Under the same culture conditions however, RA treatment did not induce morphological changes in the K266 cell line and the expression of CKs 5/14 was not significantly reduced. These findings suggest that the modulation of CK19 and CKs 5/14 expression observed in mammary carcinoma cells upon RA treatment might be regulated through different pathways.


Subject(s)
Keratins/physiology , Mammary Neoplasms, Experimental/drug therapy , Mammary Neoplasms, Experimental/physiopathology , Tretinoin/pharmacology , Animals , Cats , Down-Regulation/drug effects , Down-Regulation/physiology , Humans , Immunohistochemistry , Keratins/analysis , Mammary Neoplasms, Experimental/chemistry , Mice , Mice, Inbred BALB C , Mice, Nude , Microscopy, Electron , Neoplasm Transplantation , Tumor Cells, Cultured/drug effects
20.
Am J Vet Res ; 54(7): 1095-102, 1993 Jul.
Article in English | MEDLINE | ID: mdl-7690208

ABSTRACT

Expression of keratins (cytokeratins, CK) known to be suitable markers for different types of epithelial differentiation was analyzed in specimens of feline mammary tissue. A panel of specific anti-CK monoclonal antibodies (MAb) was used to determine CK distribution pattern in normal feline tissues (n = 3), and in benign (n = 18) and malignant (n = 20) feline mammary tumors. In selected tumors, the CK distribution pattern was also determined by biochemical methods. A MAb specific for alpha-smooth muscle actin was used to discriminate between myoepithelial cells and luminal epithelial cells. In normal mammary gland tissues, 6 MAb reacted exclusively, either with myoepithelial cells or with luminal epithelial cells. Luminal epithelial cells reacted with MAb specific for CK typical of simple epithelia, whereas myoepithelial cells reacted with MAb specific for CK in basal cells of stratified epithelia. A similar distribution of CK was detected in specimens from benign tumors, except that CK4 was not detected in normal mammary gland tissues and was detected in some ducts in specimens with adenosis. Almost all tumor cells in specimens from malignant tumors reacted with MAb specific for CK typical of simple epithelia. Concomitant expression of CK typical of stratified epithelia was detected in small or large subpopulations of tumor cells in 70% of carcinomas. Cytokeratins typical of basal cell layers and typical for suprabasal layers of inner stratified epithelia were detected. Cytokeratins typical of stratified epithelia were always found in areas of squamous metaplasia, but also were found in adenocarcinomal cells surrounding these areas.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma/veterinary , Cat Diseases , Keratins/analysis , Mammary Glands, Animal/cytology , Mammary Glands, Animal/pathology , Mammary Neoplasms, Animal/pathology , Precancerous Conditions/veterinary , Adenofibroma/pathology , Adenofibroma/veterinary , Animals , Antibodies, Monoclonal , Carcinoma/pathology , Cats , Electrophoresis, Gel, Two-Dimensional , Metaplasia , Precancerous Conditions/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...